Krystyna M Kazmierczak

Summary

Affiliation: International Health Management Associates
Country: USA

Publications

  1. Karlowsky J, Kazmierczak K, Bouchillon S, De Jonge B, Stone G, Sahm D. In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012-2015. Antimicrob Agents Chemother. 2019;: pubmed publisher
    ..Country-specific variations were noted in the susceptibility of P. aeruginosa isolates to ceftazidime-avibactam. ..
  2. Kazmierczak K, Tsuji M, Wise M, Hackel M, Yamano Y, Echols R, et al. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-. Int J Antimicrob Agents. 2018;: pubmed publisher
  3. Kazmierczak K, Bradford P, Stone G, De Jonge B, Sahm D. In Vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015. Antimicrob Agents Chemother. 2018;62: pubmed publisher
  4. Karlowsky J, Kazmierczak K, Bouchillon S, De Jonge B, Stone G, Sahm D. In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015. Antimicrob Agents Chemother. 2018;62: pubmed publisher
    ..6, 83.3, and 68.2% of isolates, respectively. Overall, clinical isolates of Enterobacteriaceae and P. aeruginosa collected in nine Asia-Pacific countries from 2012 to 2015 were highly susceptible to ceftazidime-avibactam. ..
  5. Kazmierczak K, Rabine S, Hackel M, McLaughlin R, Biedenbach D, Bouchillon S, et al. Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016;60:1067-78 pubmed publisher
    ..Although the global percentage of isolates encoding MBLs remains relatively low, their detection in 12 species, 34 countries, and all regions participating in this surveillance study is concerning. ..
  6. Karlowsky J, Biedenbach D, Kazmierczak K, Stone G, Sahm D. Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014. Antimicrob Agents Chemother. 2016;60:2849-57 pubmed publisher
    ..oxytoca, and P. mirabilis We conclude that ceftazidime-avibactam demonstrates potent in vitro activity against globally collected clinical isolates of Enterobacteriaceae, including isolates producing ESBLs and AmpC β-lactamases. ..
  7. Hackel M, Kazmierczak K, Hoban D, Biedenbach D, Bouchillon S, De Jonge B, et al. Assessment of the In Vitro Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014. Antimicrob Agents Chemother. 2016;60:4677-83 pubmed publisher
    ..These in vitro results support the continued investigation of ceftazidime-avibactam for the treatment of MDR Klebsiella species infections. ..
  8. Nichols W, De Jonge B, Kazmierczak K, Karlowsky J, Sahm D. In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014). Antimicrob Agents Chemother. 2016;60:4743-9 pubmed publisher
    ..aeruginosa, including isolates that are resistant to ceftazidime and meropenem. ..
  9. Bradford P, Kazmierczak K, Biedenbach D, Wise M, Hackel M, Sahm D. Correlation of β-Lactamase Production and Colistin Resistance among Enterobacteriaceae Isolates from a Global Surveillance Program. Antimicrob Agents Chemother. 2015;60:1385-92 pubmed publisher
    ..However, the wide geographic dispersion of colistin resistance within diverse genus and species groups and the higher incidence observed among carbapenemase-producing MDR pathogens are concerning. ..

More Information

Publications14

  1. De Jonge B, Karlowsky J, Kazmierczak K, Biedenbach D, Sahm D, Nichols W. In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014). Antimicrob Agents Chemother. 2016;60:3163-9 pubmed publisher
    ..7% susceptibility to ceftazidime-avibactam. Ceftazidime-avibactam activity was compromised only in isolates for which carbapenem resistance was mediated through metallo-β-lactamases. ..
  2. Kazmierczak K, Biedenbach D, Hackel M, Rabine S, De Jonge B, Bouchillon S, et al. Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam. Antimicrob Agents Chemother. 2016;60:4490-500 pubmed publisher
    ..aeruginosa This analysis of surveillance data demonstrated that KPC is widely disseminated. KPC was found in multiple species of Enterobacteriaceae and P. aeruginosa and has now become a global problem. ..
  3. Kazmierczak K, Lob S, Hoban D, Hackel M, Badal R, Bouchillon S. Characterization of extended-spectrum beta-lactamases and antimicrobial resistance of Klebsiella pneumoniae in intra-abdominal infection isolates in Latin America, 2008-2012. Results of the Study for Monitoring Antimicrobial Resistance Trends. Diagn Microbiol Infect Dis. 2015;82:209-14 pubmed publisher
    ..pneumoniae, as well as for cefepime, cefotaxime, cefoxitin, ceftriaxone, ertapenem, and imipenem among ESBL-positive isolates, while susceptibility of ESBL-negative isolates to ampicillin-sulbactam actually increased (P < 0.05). ..
  4. Lob S, Hackel M, Kazmierczak K, Hoban D, Young K, Motyl M, et al. Invitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - Results from the SMART global surveillance program. Diagn Microbiol Infect Dis. 2017;88:171-176 pubmed publisher
    ..aeruginosa. ..
  5. Karlowsky J, Kazmierczak K, De Jonge B, Hackel M, Sahm D, Bradford P. In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015. Antimicrob Agents Chemother. 2017;61: pubmed publisher